S&P 500   3,157.15 (-2.13%)
DOW   27,328.77 (-2.26%)
QQQ   217.52 (-1.75%)
AAPL   293.15 (-1.69%)
FB   199.76 (-0.48%)
MSFT   169.83 (-0.62%)
AMZN   1,980.68 (-1.42%)
CGC   19.48 (-4.04%)
NVDA   262.32 (-4.01%)
BABA   206.06 (-0.05%)
MU   52.22 (-5.07%)
GE   11.33 (-4.55%)
TSLA   800.00 (-4.05%)
AMD   47.86 (-2.59%)
ACB   1.50 (-3.23%)
F   7.32 (-3.30%)
NFLX   362.53 (-1.67%)
BAC   31.45 (-3.91%)
GILD   69.99 (-3.99%)
S&P 500   3,157.15 (-2.13%)
DOW   27,328.77 (-2.26%)
QQQ   217.52 (-1.75%)
AAPL   293.15 (-1.69%)
FB   199.76 (-0.48%)
MSFT   169.83 (-0.62%)
AMZN   1,980.68 (-1.42%)
CGC   19.48 (-4.04%)
NVDA   262.32 (-4.01%)
BABA   206.06 (-0.05%)
MU   52.22 (-5.07%)
GE   11.33 (-4.55%)
TSLA   800.00 (-4.05%)
AMD   47.86 (-2.59%)
ACB   1.50 (-3.23%)
F   7.32 (-3.30%)
NFLX   362.53 (-1.67%)
BAC   31.45 (-3.91%)
GILD   69.99 (-3.99%)
S&P 500   3,157.15 (-2.13%)
DOW   27,328.77 (-2.26%)
QQQ   217.52 (-1.75%)
AAPL   293.15 (-1.69%)
FB   199.76 (-0.48%)
MSFT   169.83 (-0.62%)
AMZN   1,980.68 (-1.42%)
CGC   19.48 (-4.04%)
NVDA   262.32 (-4.01%)
BABA   206.06 (-0.05%)
MU   52.22 (-5.07%)
GE   11.33 (-4.55%)
TSLA   800.00 (-4.05%)
AMD   47.86 (-2.59%)
ACB   1.50 (-3.23%)
F   7.32 (-3.30%)
NFLX   362.53 (-1.67%)
BAC   31.45 (-3.91%)
GILD   69.99 (-3.99%)
S&P 500   3,157.15 (-2.13%)
DOW   27,328.77 (-2.26%)
QQQ   217.52 (-1.75%)
AAPL   293.15 (-1.69%)
FB   199.76 (-0.48%)
MSFT   169.83 (-0.62%)
AMZN   1,980.68 (-1.42%)
CGC   19.48 (-4.04%)
NVDA   262.32 (-4.01%)
BABA   206.06 (-0.05%)
MU   52.22 (-5.07%)
GE   11.33 (-4.55%)
TSLA   800.00 (-4.05%)
AMD   47.86 (-2.59%)
ACB   1.50 (-3.23%)
F   7.32 (-3.30%)
NFLX   362.53 (-1.67%)
BAC   31.45 (-3.91%)
GILD   69.99 (-3.99%)
Log in

NYSE:NVRO - Nevro Stock Price, Forecast & News

$132.45
-3.04 (-2.24 %)
(As of 02/25/2020 02:01 PM ET)
Today's Range
$131.84
Now: $132.45
$137.46
50-Day Range
$114.31
MA: $130.59
$144.31
52-Week Range
$42.82
Now: $132.45
$145.56
Volume148,337 shs
Average Volume389,843 shs
Market Capitalization$4.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.46
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone650-251-0005

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$387.29 million
Book Value$8.14 per share

Profitability

Net Income$-49,210,000.00

Miscellaneous

Employees804
Market Cap$4.11 billion
Next Earnings Date2/25/2020 (Confirmed)
OptionableOptionable

Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.


Nevro (NYSE:NVRO) Frequently Asked Questions

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

How were Nevro's earnings last quarter?

Nevro Corp (NYSE:NVRO) issued its earnings results on Wednesday, November, 6th. The medical equipment provider reported ($0.58) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.85) by $0.27. The medical equipment provider earned $100.16 million during the quarter, compared to the consensus estimate of $92.27 million. Nevro had a negative net margin of 25.94% and a negative return on equity of 46.35%. Nevro's revenue was up 4.7% on a year-over-year basis. During the same period last year, the business posted ($0.37) EPS. View Nevro's Earnings History.

When is Nevro's next earnings date?

Nevro is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Nevro.

What guidance has Nevro issued on next quarter's earnings?

Nevro issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Tuesday, January, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $114.4-114.4 million, compared to the consensus revenue estimate of $109.73 million.

What price target have analysts set for NVRO?

12 equities research analysts have issued 12-month price objectives for Nevro's stock. Their forecasts range from $65.00 to $150.00. On average, they expect Nevro's share price to reach $103.83 in the next twelve months. This suggests that the stock has a possible downside of 22.0%. View Analyst Price Targets for Nevro.

What is the consensus analysts' recommendation for Nevro?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nevro.

Has Nevro been receiving favorable news coverage?

Media coverage about NVRO stock has trended very negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nevro earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Nevro.

Are investors shorting Nevro?

Nevro saw a decrease in short interest in January. As of January 31st, there was short interest totalling 2,610,000 shares, a decrease of 9.1% from the January 15th total of 2,870,000 shares. Based on an average trading volume of 443,000 shares, the days-to-cover ratio is presently 5.9 days. Currently, 8.8% of the shares of the stock are short sold. View Nevro's Current Options Chain.

Who are some of Nevro's key competitors?

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), Gilead Sciences (GILD), AbbVie (ABBV), Incyte (INCY), Micron Technology (MU), Starbucks (SBUX), ABIOMED (ABMD), Celgene (CELG) and Intercept Pharmaceuticals (ICPT).

Who are Nevro's key executives?

Nevro's management team includes the folowing people:
  • Mr. Andrew H. Galligan, Chief Financial Officer (Age 63)
  • Mr. Patrick Schmitz, VP of Operations (Age 59)
  • Mr. Kashif Rashid, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 45)
  • Mr. Doug Alleavitch, VP of Quality (Age 58)
  • Mr. D. Keith Grossman, Pres, CEO & Director (Age 59)

Who are Nevro's major shareholders?

Nevro's stock is owned by a number of of retail and institutional investors. Top institutional investors include Fred Alger Management LLC (6.17%), Franklin Resources Inc. (4.30%), Jackson Square Partners LLC (3.91%), Perceptive Advisors LLC (2.46%), State Street Corp (2.29%) and Lord Abbett & CO. LLC (1.92%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle, Shawn Mccormick and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.

Which institutional investors are selling Nevro stock?

NVRO stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Jackson Square Partners LLC, Perceptive Advisors LLC, Point72 Asset Management L.P., Franklin Resources Inc., Barclays PLC, Spark Investment Management LLC and Lord Abbett & CO. LLC. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Doug Alleavitch and Shawn Mccormick. View Insider Buying and Selling for Nevro.

Which institutional investors are buying Nevro stock?

NVRO stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Renaissance Technologies LLC, Partner Fund Management L.P., AXA, Man Group plc, Geode Capital Management LLC and State of New Jersey Common Pension Fund D. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman and Kevin C Oboyle. View Insider Buying and Selling for Nevro.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $133.14.

How big of a company is Nevro?

Nevro has a market capitalization of $4.13 billion and generates $387.29 million in revenue each year. The medical equipment provider earns $-49,210,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Nevro employs 804 workers across the globe.View Additional Information About Nevro.

What is Nevro's official website?

The official website for Nevro is http://www.nevro.com/.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]


MarketBeat Community Rating for Nevro (NYSE NVRO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  424 (Thanks for Voting!)
Underperform Votes:  301 (Thanks for Voting!)
Total Votes:  725
MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel